Bioventix (51B) Stock Overview
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
51B Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Bioventix PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£17.30 |
| 52 Week High | UK£33.00 |
| 52 Week Low | UK£14.90 |
| Beta | 0.55 |
| 1 Month Change | -6.99% |
| 3 Month Change | 8.81% |
| 1 Year Change | -44.90% |
| 3 Year Change | -59.58% |
| 5 Year Change | -63.96% |
| Change since IPO | -45.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| 51B | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -8.0% | 0.1% | -0.2% |
| 1Y | -44.9% | -8.1% | 1.4% |
Return vs Industry: 51B underperformed the German Biotechs industry which returned -8.1% over the past year.
Return vs Market: 51B underperformed the German Market which returned 1.4% over the past year.
Price Volatility
| 51B volatility | |
|---|---|
| 51B Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 13.1% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 51B has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 51B's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 12 | Peter Harrison | www.bioventix.com |
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. The company also provides contract SMAs services; and industrial and environmental biomonitoring platform, which reduces the time between sampling and results.
Bioventix PLC Fundamentals Summary
| 51B fundamental statistics | |
|---|---|
| Market cap | €98.42m |
| Earnings (TTM) | €8.62m |
| Revenue (TTM) | €14.54m |
Is 51B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 51B income statement (TTM) | |
|---|---|
| Revenue | UK£12.54m |
| Cost of Revenue | UK£947.46k |
| Gross Profit | UK£11.59m |
| Other Expenses | UK£4.16m |
| Earnings | UK£7.44m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.42 |
| Gross Margin | 92.45% |
| Net Profit Margin | 59.30% |
| Debt/Equity Ratio | 0% |
How did 51B perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/15 07:46 |
| End of Day Share Price | 2026/06/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bioventix PLC is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Adam McCarter | Cavendish |